Q: Hello,
in your response to Robert's question on December 14th about uranium names to play, you mentioned DML and EFR but not NXE. I know your general feeling towards the sector and in your last comment about NXE in February of this year you stated that it is pre-revenue and will probably be next year as well.
I do note that 3 analysts consider it a moderate buy, and one a strong buy. It's share price has been trending up since the pandemic sell-off earlier this year, and it has caught the updraft that has moved most uranium stocks over the last month or so.
I'd appreciate hearing any updated views you may have on this one.
Marc.
in your response to Robert's question on December 14th about uranium names to play, you mentioned DML and EFR but not NXE. I know your general feeling towards the sector and in your last comment about NXE in February of this year you stated that it is pre-revenue and will probably be next year as well.
I do note that 3 analysts consider it a moderate buy, and one a strong buy. It's share price has been trending up since the pandemic sell-off earlier this year, and it has caught the updraft that has moved most uranium stocks over the last month or so.
I'd appreciate hearing any updated views you may have on this one.
Marc.